%0 Journal Article
%T Consensus recommendations for the use of novel antiretrovirals in persons with HIV who are heavily treatment-experienced and/or have multidrug-resistant HIV-1: Endorsed by the American Academy of HIV Medicine, American College of Clinical Pharmacy.
%A Cluck DB
%A Chastain DB
%A Murray M
%A Durham SH
%A Chahine EB
%A Derrick C
%A Dumond JB
%A Hester EK
%A Jeter SB
%A Johnson MD
%A Kilcrease C
%A Kufel WD
%A Kwong J
%A Ladak AF
%A Patel N
%A Pérez SE
%A Poe JB
%A Bolch C
%A Thomas I
%A Asiago-Reddy E
%A Short WR
%J Pharmacotherapy
%V 44
%N 5
%D 2024 May
%M 38853601
%F 6.251
%R 10.1002/phar.2914
%X Treatment options are currently limited for persons with HIV-1 (PWH) who are heavily treatment-experienced and/or have multidrug-resistant HIV-1. Three agents have been approved by the U.S. Food and Drug Administration (FDA) since 2018, representing a significant advancement for this population: ibalizumab, fostemsavir, and lenacapavir. However, there is a paucity of recommendations endorsed by national and international guidelines describing the optimal use (e.g., selection and monitoring after initiation) of these novel antiretrovirals in this population. To address this gap, a modified Delphi technique was used to develop these consensus recommendations that establish a framework for initiating and managing ibalizumab, fostemsavir, or lenacapavir in PWH who are heavily treatment-experienced and/or have multidrug-resistant HIV-1. In addition, future areas of research are also identified and discussed.